Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Take A Look At Gilead Sciences

By Joshua RodriguezStock MarketsAug 28, 2015 02:18AM ET
www.investing.com/analysis/gilead-sciences-%28gild%29-stock:-don%E2%80%99t-miss-this-opportunity-263262
Take A Look At Gilead Sciences
By Joshua Rodriguez   |  Aug 28, 2015 02:18AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
GILD
-0.45%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
+0.21%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Gilead Sciences (NASDAQ:GILD)

I’ve been covering Gilead Sciences for quite some time now; and I’m proud that through the ups and downs, I’ve maintained my bullish opinion on the stock. The reality is that GILD has one of the most interesting success stories in biotechnology today; and the story keeps getting better! Here’s why you may be missing out on an opportunity if this stock is not in your portfolio…

Gilead Sciences Has An Impressive History

First and foremost, Gilead Sciences has an incredible track record. Starting with the hepatitis C market; the company pretty much controls it! Although concerns started to rise earlier this year about GILD’s ability to maintain control of the HCV market as AbbVie stepped in, the company proved that they have a stronghold on the market.

It’s also important to look at GILD’s earnings history. The bottom line is that this company has a strong history of producing incredible earnings reports. According to Street Insider, Gilead Sciences has produced earnings above analyst expectations for 7 out of the last 8 quarters; including the past 3 consecutive quarters. The only miss in the bunch wasn’t missed by much!

GILD Is Heavily Undervalued

Another metric I like to pay attention to when choosing stocks to cover is valuation; and when it comes to GILD their valuation is pristine. The reality is that in today’s market, it can be difficult to find a stock that isn’t overvalued; meaning that good value for your money is hard to come by. However, Gilead Sciences is great in that respect. Currently, a PE ratio under 17 is great. Now, try a PE ratio under 10! According to NASDAQ, Gilead’s price to earnings is only 8.55; about half of what investors should be looking for. That insinuates incredible upside potential and one heck of an opportunity.

More Good News Continues To Pop Up

Gilead Sciences also has a knack for producing positive news time and time again; and since news has a tendency of causing moves in the market, that’s great for investors. Most recently, the company announced data from it’s AMBITION study. AMBITION is a collaboration between GILD and GSK. The study is looking into a combined therapy that combines Letairis and tadalafil in an attempt to treat patients with pulmonary arterial hypertension. New data from the AMBITION study shows that the combined treatment reduced the risk of clinical failure by 50% when compared to Letairis and tadalafil monotherapy. Following the announcement of data, University of California’s Emeritus Professor, Lewis J. Rubin, MD., had the following to say…

The only other published, large scale, event-driven study to date in PAH compared an endothelin receptor antagonist to placebo in patients who were either treatment-naive or on background therapy, however, all patients in AMBITION received an approved therapy for PAH… Thus, the magnitude of the effect with this combination in comparison to active monotherapy is impressive, particularly in WHO functional calss II patients were we observed nearly an 80 percent reduction in the risk of clinical failure versus monotherapy.”

The Bottom Line

The bottom line is that GILD is a great stock. The company has a stronghold on the HCV market, is incredibly effective in the HIV market and is continually finding new medical ailments to tackle. Combining the company’s successes with an incredibly low valuation makes this an incredibly strong buy!

Take A Look At Gilead Sciences
 

Related Articles

David Moenning
Has a New Bull Arrived? By David Moenning - Jan 30, 2023 5

In last week's meandering market missive, I opined that, "the next major trend - in either direction - is likely to be driven by the outlook/expectation for the state of the...

Take A Look At Gilead Sciences

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email